Business Description
![Gilead Sciences Inc Gilead Sciences Inc logo](https://static.gurufocus.com/logos/0C000007VR.png?14)
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US3755581036
Share Class Description:
LTS:0QYQ: Ordinary SharesCompare
Compare
Traded in other countries / regions
GILD.USA0QYQ.UKGIS.GermanyGILD.Argentina1GILD.ItalyGILD.MexicoGILD.AustriaGILD.PeruGILD34.BrazilGILD.Chile IPO Date
2018-01-15Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.28 | |||||
Debt-to-EBITDA | 4.43 | |||||
Interest Coverage | 7.4 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.62 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.3 | |||||
3-Year EBITDA Growth Rate | 36.6 | |||||
3-Year EPS without NRI Growth Rate | 24.5 | |||||
3-Year FCF Growth Rate | -0.3 | |||||
3-Year Book Growth Rate | 8.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 1.85 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 82.53 | |||||
9-Day RSI | 69.33 | |||||
14-Day RSI | 64.34 | |||||
6-1 Month Momentum % | -3.65 | |||||
12-1 Month Momentum % | -7.72 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 0.95 | |||||
Cash Ratio | 0.26 | |||||
Days Inventory | 96.91 | |||||
Days Sales Outstanding | 60.42 | |||||
Days Payable | 31.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.96 | |||||
Dividend Payout Ratio | 0.72 | |||||
3-Year Dividend Growth Rate | 3.3 | |||||
Forward Dividend Yield % | 4.01 | |||||
5-Year Yield-on-Cost % | 5.24 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 5.31 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.72 | |||||
Operating Margin % | 25.94 | |||||
Net Margin % | 3.79 | |||||
FCF Margin % | 24.8 | |||||
ROE % | 5.16 | |||||
ROA % | 1.77 | |||||
ROIC % | 9.49 | |||||
ROC (Joel Greenblatt) % | 45.41 | |||||
ROCE % | 5.33 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 93.56 | |||||
Forward PE Ratio | 20.48 | |||||
PE Ratio without NRI | 18.23 | |||||
Shiller PE Ratio | 12.59 | |||||
PEG Ratio | 3.44 | |||||
PS Ratio | 3.46 | |||||
PB Ratio | 5.23 | |||||
Price-to-Free-Cash-Flow | 13.93 | |||||
Price-to-Operating-Cash-Flow | 12.87 | |||||
EV-to-EBIT | 46.2 | |||||
EV-to-Forward-EBIT | 15.54 | |||||
EV-to-EBITDA | 22.03 | |||||
EV-to-Forward-EBITDA | 12.27 | |||||
EV-to-Revenue | 4.18 | |||||
EV-to-Forward-Revenue | 4.2 | |||||
EV-to-FCF | 16.83 | |||||
Price-to-Projected-FCF | 1.03 | |||||
Price-to-Median-PS-Value | 0.93 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.18 | |||||
Earnings Yield (Greenblatt) % | 2.16 | |||||
FCF Yield % | 7.22 | |||||
Forward Rate of Return (Yacktman) % | 17.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gilead Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 27,803 | ||
EPS (TTM) ($) | 0.82 | ||
Beta | 0.3 | ||
Volatility % | 13.76 | ||
14-Day RSI | 64.34 | ||
14-Day ATR ($) | 1.576262 | ||
20-Day SMA ($) | 75.0825 | ||
12-1 Month Momentum % | -7.72 | ||
52-Week Range ($) | 62.14 - 87.525 | ||
Shares Outstanding (Mil) | 1,244.99 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Gilead Sciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Gilead Sciences Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Gilead Sciences Inc Frequently Asked Questions
What is Gilead Sciences Inc(LTS:0QYQ)'s stock price today?
The current price of LTS:0QYQ is $76.76. The 52 week high of LTS:0QYQ is $87.53 and 52 week low is $62.14.
When is next earnings date of Gilead Sciences Inc(LTS:0QYQ)?
The next earnings date of Gilead Sciences Inc(LTS:0QYQ) is 2024-11-07 Est..
Does Gilead Sciences Inc(LTS:0QYQ) pay dividends? If so, how much?
The Dividend Yield %  of Gilead Sciences Inc(LTS:0QYQ) is 3.96% (As of Today), Highest Dividend Payout Ratio of Gilead Sciences Inc(LTS:0QYQ) was 0.78. The lowest was 0.11. And the median was 0.48. The  Forward Dividend Yield % of Gilead Sciences Inc(LTS:0QYQ) is 4.01%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |